|
🐜
|
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
59 auth.
P. Horák,
C. Heining,
S. Kreutzfeldt,
B. Hutter,
A. Mock,
Jennifer Hullein,
Martina Frohlich,
S. Uhrig,
A. Jahn,
A. Rump,
L. Gieldon,
L. Mohrmann,
D. Hanf,
V. Teleanu,
C. Heilig,
...
D. Lipka,
Michael Allgauer,
L. Ruhnke,
A. Lassmann,
V. Endris,
O. Neumann,
R. Penzel,
K. Beck,
D. Richter,
U. Winter,
S. Wolf,
Katrin Pfutze,
C. Georg,
B. Meissburger,
I. Buchhalter,
M. Augustin,
W. Aulitzky,
P. Hohenberger,
M. Kroiss,
P. Schirmacher,
R. Schlenk,
U. Keilholz,
F. Klauschen,
G. Folprecht,
S. Bauer,
J. Siveke,
C. Brandts,
T. Kindler,
M. Boerries,
A. Illert,
N. von Bubnoff,
P. Jost,
K. Spiekermann,
M. Bitzer,
K. Schulze-Osthoff,
C. von Kalle,
B. Klink,
B. Brors,
A. Stenzinger,
E. Schrock,
Daniel Hubschmann,
W. Weichert,
H. Glimm,
Stefan Frohling
|
7 |
2021 |
7
🐜
|
|
🐜
|
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
21 auth.
J. Duell,
K. Maddocks,
E. González-Barca,
W. Jurczak,
A. Liberati,
S. de Vos,
Z. Nagy,
A. Obr,
G. Gaidano,
P. Abrisqueta,
...
N. Kalakonda,
M. André,
M. Dreyling,
T. Menne,
O. Tournilhac,
M. Augustin,
A. Rosenwald,
M. Dirnberger-Hertweck,
J. Weirather,
S. Ambarkhane,
G. Salles
|
6 |
2021 |
6
🐜
|
|
🐜
|
Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
18 auth.
E. Yu,
C. Massard,
M. Retz,
A. Tafreshi,
J. C. Galcerán,
P. Hammerer,
P. Fong,
N. Shore,
A. Joshua,
M. Linch,
...
H. Gurney,
E. Romano,
M. Augustin,
J. Piulats,
Haiyan Wu,
C. Schloss,
C. Poehlein,
J. Bono
|
5 |
2019 |
5
🐜
|
|
🐜
|
KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
20 auth.
E. Yu,
J. Piulats,
G. Gravis,
B. Laguerre,
J. A. Arija,
S. Oudard,
P. Fong,
M. Kolinsky,
M. Augustin,
S. Feyerabend,
...
Audrey E. Kam,
H. Gurney,
A. Tafreshi,
M. Retz,
W. Berry,
N. Mar,
Helen Wu,
C. Schloss,
C. Poehlein,
J. Bono
|
5 |
2020 |
5
🐜
|
|
🐜
|
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
21 auth.
E. Yu,
J. Piulats,
G. Gravis,
P. Fong,
T. Todenhöfer,
B. Laguerre,
J. Arranz,
S. Oudard,
C. Massard,
J. Heinzelbecker,
...
L. Nordquist,
J. Carles,
M. Kolinsky,
M. Augustin,
H. Gurney,
A. Tafreshi,
X. Li,
P. Qiu,
C. Poehlein,
C. Schloss,
J. D. de Bono
|
5 |
2022 |
5
🐜
|
|
🐜
|
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
77 auth.
A. Jahn,
A. Rump,
T. Widmann,
C. Heining,
P. Horák,
B. Hutter,
N. Paramasivam,
S. Uhrig,
L. Gieldon,
S. Drukewitz,
A. Kübler,
M. Bermúdez,
K. Hackmann,
J. Porrmann,
J Wagner,
...
M. Arlt,
M. Franke,
J. Fischer,
Z. Kowalzyk,
D. William,
V. Weth,
S. Oster,
M. Fröhlich,
J. Hüllein,
C. Valle González,
S. Kreutzfeldt,
A. Mock,
C. Heilig,
D. Lipka,
L. Möhrmann,
D. Hanf,
V. Teleanu,
M. Allgäuer,
L. Ruhnke,
O. Kutz,
A. Knurr,
A. Lassmann,
V. Endris,
O. Neumann,
R. Penzel,
K. Beck,
D. Richter,
U. Winter,
S. Wolf,
K. Pfütze,
C. Geörg,
B. Meissburger,
I. Buchhalter,
M. Augustin,
W. Aulitzky,
P. Hohenberger,
M. Kroiss,
P. Schirmacher,
R. Schlenk,
U. Keilholz,
F. Klauschen,
G. Folprecht,
S. Bauer,
J. Siveke,
C. Brandts,
T. Kindler,
M. Boerries,
A. Illert,
N. von Bubnoff,
P. J. Jost,
K. Metzeler,
M. Bitzer,
K. Schulze-Osthoff,
C. von Kalle,
B. Brors,
A. Stenzinger,
W. Weichert,
D. Hübschmann,
S. Fröhling,
H. Glimm,
E. Schröck,
B. Klink
|
5 |
2022 |
5
🐜
|
|
🐜
|
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study
9 auth.
J. Duell,
A. Obr,
M. Augustin,
J. Endell,
Hao Liu,
S. Geiger,
...
I. Silverman,
S. Ambarkhane,
A. Rosenwald
|
3 |
2021 |
3
🐜
|
|
🐜
|
Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
20 auth.
E. Yu,
José Raúl Rodríguez Rodríguez,
G. Gravis,
B. Laguerre,
J. A. Arija,
S. Oudard,
P. Fong,
M. Kolinsky,
M. Augustin,
T. Todenhöfer,
...
Audrey E. Kam,
H. Gurney,
A. Tafreshi,
M. Retz,
W. Berry,
N. Mar,
Haiyan Wu,
P. Qiu,
C. Schloss,
J. Bono
|
3 |
2020 |
3
🐜
|
